https://de.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/MorphoSys-AG-Ad-hoc-Primarer-Endpunkt-der-L-MIND-Studie-einer-Kombinationsstudie-von-Tafasitamab-28610981/?utm_source=telegram&utm_medium=social&utm_campaign=share